NCT05835609招募中1 期
Phase I, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM534 Administered Intravenously to Patients With Advanced Solid Tumors
PharmaMar3 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2022年12月23日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 30
- 试验地点
- 3
- 主要终点
- Determination of the Maximum Tolerated Dose and the Recommended Dose
研究概览
简要总结
The goals of this trial are to identify the dose limiting toxicities, to determine the maximum tolerated dose and the recommended dose of PM534 in patients with advanced solid tumors. All Patients will receive PM534 via intravenous.
详细描述
This is a prospective, open-label, dose-escalating phase I study in patients with advanced solid tumors. Patients will be included in cohorts of a minimum of three or six patients to receive PM534 at successively increasing dose levels.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Voluntarily signed and dated written informed consent, obtained prior to any specific study procedure.
- •Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤1
- •Patients must have:
- •3.1 Pathologically confirmed diagnosis of advanced solid tumors 3.2 No more than three prior chemotherapy lines.
- •Patients with measurable or non-measurable disease according to the RECIST v.1.
- •Recovery to grade ≤1 from drug-related adverse events (AEs) of previous disease treatments, excluding grade 2 alopecia.
- •Laboratory values within seven days prior to first infusion:
- •Absolute neutrophil count (ANC) ≥1.5 x 10⁹/L, platelet count ≥100 x 10⁹/L and hemoglobin ≥9 g/dL
- •Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3.0 x upper limit of normal (ULN).
- •Total bilirubin ≤ULN (up to 1.5 x ULN for patients with Gilbert's syndrome).
- •Creatinine clearance ≥30 mL/min or serum creatinine ≤1.5 x ULN.
- •Serum albumin ≥3 g/dL.
- •Serum potassium ≥3.5 mmol/L.
- •Serum magnesium ≥1.6 mg/dL.
- •Wash-out periods:
- •At least three weeks since the last chemotherapy.
- •At least four weeks since the last monoclonal antibody (MAb)-containing therapy.
- •At least two weeks since the last biological/investigational single-agent therapy (excluding MAbs) and/or palliative radiotherapy (RT).
- •In patients with hormone-sensitive breast cancer progressing while on hormone therapy (except for luteinizing hormone-releasing hormone [LHRH] analogues in pre-menopausal women or megestrol acetate), all other hormonal therapies must be stopped at least one week before study treatment start.
- •Castrate-resistant prostate cancer (CRPC) patients may continue receiving hormone therapy prior to and during study treatment.
- •Life expectancy ≥3 months
排除标准
- •Concomitant diseases/conditions:
- •Increased cardiac risk:
- •History of long QT syndrome.
- •Corrected QT interval (QTcF, Fridericia correction) ≥450 msec on screening electrocardiogram (ECG).
- •History of or current ischemic heart disease, including myocardial infarction, stable/unstable angina, coronary arteriography or cardiac stress testing with findings consistent with coronary occlusion or infarction or symptomatic arrhythmia.
- •History of heart failure or left ventricular dysfunction (left ventricular ejection fraction [LVEF] ≤50%) by multiple-gated acquisition scan (MUGA) or echocardiography (ECHO).
- •Clinically significant ECG abnormalities, including any of the following: right bundle branch block with left anterior hemiblock, second (Mobitz II) or third degree atrioventricular block and findings suggestive of ischemic heart disease.
- •Symptomatic arrhythmia.
- •Use of a cardiac pacemaker.
- •History of or current peripheral vascular disease or cerebrovascular disease.
- •Presence of:
- •Any grade of peripheral neuropathy (any etiology) at study entry.
- •Prior history of grade ≥ 2 peripheral neuropathy due to any chemotherapeutic or investigational agent.
- •Clinical or radiological signs of subocclusion/bowel obstruction.
- •Active infection requiring systemic treatment.
- •Known human immunodeficiency virus (HIV) or known hepatitis C virus (HCV) infection or active hepatitis B.
- •Any other major illness that, in the Investigator's judgment, will substantially increase the risk associated with the patient's participation in this study
- •Symptomatic, steroid-requiring, central nervous system (CNS) disease.
- •Patients with carcinomatous meningitis.
- •Prior bone marrow or stem cell transplantation.
- •Current treatment with colchicine.
- •Use of (strong or moderate) inhibitors or strong inducers of CYP3A4 activity within two weeks prior to the first infusion of PM534
- •Known hypersensitivity to any of the components of the drug product.
- •Limitation of the patient's ability to comply with the treatment or to follow the protocol procedures.
- •Women who are pregnant or breast feeding and fertile patients (men and women) who are not using an effective method of contraception
- •Patients with pulmonary lymphangitis.
- •Use of medications with known risk of inducing torsades de pointes (TdP) within five half-lives prior to the first infusion of PM534
研究组 & 干预措施
PM534
Experimental
Patients will be included in cohorts of a minimum of three or six patients to receive PM534 at successively increasing dose levels.
干预措施: PM534 (Drug)
结局指标
主要结局
Determination of the Maximum Tolerated Dose and the Recommended Dose
时间窗: From the date of first infusion of PM534 to the date of study termination, up to 46 months
A fully evaluable patient is a patient evaluable for the primary objective (i.e., determination of the MTD and the RD).
次要结局
- Safety AEs of PM534(From the date of first infusion of PM534 to the date of study termination, up to 46 months)
- Safety Hb of PM534(From the date of first infusion of PM534 to the date of study termination, up to 46 months)
- Safety neutrophils of PM534(From the date of first infusion of PM534 to the date of study termination, up to 46 months)
- Safety platelets of PM534(From the date of first infusion of PM534 to the date of study termination, up to 46 months)
- Safety BT of PM534(From the date of first infusion of PM534 to the date of study termination, up to 46 months)
- Safety ALT/AST of PM534(From the date of first infusion of PM534 to the date of study termination, up to 46 months)
- Safety ALK of PM534(From the date of first infusion of PM534 to the date of study termination, up to 46 months)
- Safety creatinine of PM534(From the date of first infusion of PM534 to the date of study termination, up to 46 months)
- QT Assessment(During Day of Cycle 1 (each cycle lasts 21 days))
- Pharmacokinetics Cmax of PM534(Cycle 1 from all patients, and also in Cycle 2 from treated patients once the MTD has been determined(each cycle is 21 days).)
- Pharmacokinetics AUC of PM534(Cycle 1 from all patients, and also in Cycle 2 from treated patients once the MTD has been determined(each cycle is 21 days).)
- Pharmacogenomics Plasma AUC(0-t) of PM534(Cycle 1 from all patients, and also in Cycle 2 from patients treated once the MTD has been determined) (each cycle is 21 days))
- Pharmacogenomics Plasma Cmax of PM534(Cycle 1 from all patients, and also in Cycle 2 from patients treated once the MTD has been determined) (each cycle is 21 days))
- Pharmacogenomics Plasma half life of PM534(Cycle 1 from all patients, and also in Cycle 2 from patients treated once the MTD has been determined) (each cycle is 21 days))
- Pharmacogenomics Total body plasma clearance of PM534(Cycle 1 from all patients, and also in Cycle 2 from patients treated once the MTD has been determined) (each cycle is 21 days))
- Pharmacogenomics Volume of distribution of PM534(Cycle 1 from all patients, and also in Cycle 2 from patients treated once the MTD has been determined) (each cycle is 21 days))
- Pharmacogenomics Percentage of dose recovered in urine of PM534(Cycle 1 from all patients, and also in Cycle 2 from patients treated once the MTD has been determined) (each cycle is 21 days))
- Efficacy of PM534(From the date of first infusion of PM534 to the date of study termination, up to 46 months)
研究者
研究点 (3)
Loading locations...
相似试验
已完成
1 期
Safety and Efficacy of Neoadjuvant Radiochemotherapy in Adenocarcinoma of the Gastric-oesophageal JunctionEsophageal NeoplasmsStomach NeoplasmsNCT00374985Johannes Gutenberg University Mainz25
已完成
1 期
Safety Study of Combination Chemotherapy in Patients With Metastatic Solid Tumors or Adenocarcinoma of the PancreasPancreatic NeoplasmsNCT00220649St. Luke's-Roosevelt Hospital Center25
已完成
1 期
GEN1046 Safety and PK in Subjects With Advanced Solid MalignanciesSolid TumorNCT04937153Genmab18
已完成
1 期
Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced LeukemiasAcute Myelogenous LeukemiaHigh-risk Myelodysplastic SyndromeChronic Myelogenous LeukemiaAdvanced MyelofibrosisChronic Lymphocytic LeukemiaAcute Lymphoblastic LeukemiaNCT01149915Threshold Pharmaceuticals40
终止
1 期
Phase I Dose Finding Study of SSR97225 Given in Patients With Refractory CancerNeoplasmsNCT00547261Sanofi6